Literature DB >> 24981137

CORP-2 trial and the role of colchicine in nonidiopathic pericarditis.

Lovely Chhabra1, Kirandeep Dua2, David H Spodick2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24981137     DOI： 10.1038/nrcardio.2014.71-c1

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  5 in total

1.  Letter by Chhabra and Spodick regarding article, "Treatment of acute and recurrent idiopathic pericarditis".

Authors:  Lovely Chhabra; David H Spodick
Journal:  Circulation       Date:  2013-11-05       Impact factor: 29.690

2.  Long-term efficacy of interleukin-1 receptor antagonist (anakinra) in corticosteroid-dependent and colchicine-resistant recurrent pericarditis.

Authors:  Martina Finetti; Antonella Insalaco; Luca Cantarini; Antonella Meini; Luciana Breda; Maria Alessio; Matteo D'Alessandro; Paolo Picco; Alberto Martini; Marco Gattorno
Journal:  J Pediatr       Date:  2014-03-12       Impact factor: 4.406

3.  Recurrent pericarditis: can anakinra offer a promising therapy in adults with refractory symptoms?

Authors:  Lovely Chhabra; Nauman Khalid; David H Spodick
Journal:  Rev Esp Cardiol (Engl Ed)       Date:  2014-09-18

4.  Pharmacotherapy: Colchicine for recurrent pericarditis--what's new in CORP-2?

Authors:  Faisal F Syed; Bongani M Mayosi
Journal:  Nat Rev Cardiol       Date:  2014-05-27       Impact factor: 32.419

5.  Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial.

Authors:  Massimo Imazio; Riccardo Belli; Antonio Brucato; Roberto Cemin; Stefania Ferrua; Federico Beqaraj; Daniela Demarie; Silvia Ferro; Davide Forno; Silvia Maestroni; Davide Cumetti; Ferdinando Varbella; Rita Trinchero; David H Spodick; Yehuda Adler
Journal:  Lancet       Date:  2014-03-30       Impact factor: 79.321
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.